The effectiveness of insulin therapy in children with type 1 diabetes in Ukraine according to the register of patients
| Autor: | E. V. Globa, N. B. Zelinska |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Ukrainian Journal of Pediatric Endocrinology. :24-32 |
| ISSN: | 2523-4277 2304-005X |
| Popis: | Introduction. Recently, the implementation of insulin analogues into clinical practice has made it possible to optimize therapeutic regimens and regimens of insulin therapy in patients with type 1 diabetes mellitus (DM). Their advantages are manifested in a longer duration and peak-free action of prolonged-acting insulin analogues or in a more rapid onset of the effect of ultrashort insulin analogues, with less variability in their action.Aim — to analyze glycemic control in children with type 1 DM in Ukraine, who used the traditional basic-bolus insulin therapy and continuous subcutaneous insulin infusion (CSII), as well as the frequency use of different types of insulin in 2018.Matherials and methods. The analysis of glycemic control in 9283 children with type 1 DM in Ukraine in different age groups and duration of the disease, who used traditional basic-bolus insulin therapy and CSII was done. We also studied the frequency of use of various types of insulin in 2018 according to the registry of children with DM. The glycemic control was assessed using glycated hemoglobin (HbA1c).Results and discussion. According to the registry data in 2018, in Ukraine the average HbA1c level in children with type 1 DM was unsatisfactory (8.8 ± 2.01) %. When analyzing the dependence of the HbA1c level on the patient’s age and the duration of type 1 DM, it was proved that the most unsatisfactory HbA1c level was recorded in adolescent children (especially in the group of 15—17 years old), as well as in the case of DM duration up to 1 year (which is associated with high HbA1c during the onset of the disease), and later — with a longer duration of the disease (especially in the group with a duration of ≥ 10 years), (p 50 %).Conclusions. The introduction of wider use of short- and long-acting insulin analogues, as well as CSII, may create preconditions for improving glycemic control in children with type 1 DM in Ukraine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|